NCT05519865View on ClinicalTrials.gov

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Tucidinostat

30mg orally BIW

DRUG

Tislelizumab

200 mg intravenously (IV) Q3W

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY